# Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

Source: https://onco.cc/trials/nct04042831/  
OnCo record `nct04042831` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of olaparib in gallbladder cancer and other biliary tract cancers, run by Academic and Community Cancer Research United, active and no longer recruiting.

## Summary

Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations is a phase 2 interventional study registered as NCT04042831 by Academic and Community Cancer Research United, with a registry enrolment figure of 32 participants, started 2020-06-24 and due to reach its primary completion in 2025-03-12. Interventions recorded: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib. Conditions listed: Bile Duct Adenocarcinoma, Fanconi Anemia Complementation Group Gene Mutation, Metastatic Bile Duct Carcinoma, PTEN Gene Deletion. Sites: United States. Results were posted on ClinicalTrials.gov in 2026; the figures recorded here are the registry's, not a publication's.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-24
- Tags: ctgov-ingest; gallbladder-deep-dive
- Registry id: NCT04042831
- Phase: 2
- Setting: A Phase II Study of Olaparib in Patients With Advanced Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations
- Sponsor: Academic and Community Cancer Research United
- Enrolled: 32
- Outcomes: Number of Patients Alive and Progression-free at First Scan: Treatment (Olaparib) 23 participants; Overall Survival (OS): Treatment (Olaparib) 11 months; Progression-free Survival (PFS): Treatment (Olaparib) 16.9 weeks

## Sources

- ClinicalTrials.gov NCT04042831: https://clinicaltrials.gov/study/NCT04042831

## Connected records

- cancers: [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/)
- technologies: [PARP inhibitors](https://onco.cc/technologies/parp-inhibitor/)
- drugs: [Olaparib](https://onco.cc/drugs/olaparib/)
- terms: [Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)](https://onco.cc/terms/gallbladder-cancer-in-biliary-trials/)

---
JSON: https://onco.cc/api/v1/entities/nct04042831.json